Related Experiment Video
Updated: May 26, 2026

Orthotopic Rat Kidney Transplantation: A Novel and Simplified Surgical Approach
Published on: May 7, 2019
Recurrent membranoproliferative glomerulonephritis after second renal graft treated with plasmapheresis and rituximab
M J Pérez-Sáez1, K Toledo, M D Navarro
1Department of Nephrology, Hospital Universitario Reina Sofía, Córdoba, Spain. mjoseperezsaez@gmail.com
Abstract:
We present a case of a 45-year-old man who suffered from idiopatic membranoproliferative glomerulonephritis (MPGN) in the native kidney that relapsed after his first and second renal grafts. The patient was diagnosed in 1990 with lobular MPGN type I, receiving his first renal graft in 1996. In 2001, a biopsy showed recurrence of MPGN type I (rMPGN). He underwent a second renal graft in 2008. In January 2010, he experienced increased proteinuria and creatinine. Upon electron microscopy of a renal graft biopsy we diagnosed a new rMPGN. At the time of the biopsy, complement levels were normal, although C3 and C4 decreased further. We administered 12 plasmapheresis (PP) sessions and four doses of rituximab. Due to persistent renal impairment, we performed a new biopsy 3 months later, showing less severity of the acute lessions. He received a new cycle of treatment (PP+rituximab). One year later, his renal function was stable with a creatinine ranging between 2 and 2.5 mg/dL and a protein/creatinine ratio less than 1 mg/mg. We concluded that the treatment stopped the disease progression.
Insights
Membranoproliferative glomerulonephritis (MPGN) recurred in a patient after two kidney transplants. Combined plasmapheresis and rituximab treatment stabilized renal function, halting disease progression.
Area of Science:
- Nephrology
- Immunology
- Transplantation
Background:
- Idiopathic membranoproliferative glomerulonephritis (MPGN) is a rare kidney disease.
- MPGN can recur in kidney allografts, posing a significant challenge in transplantation.
Observation:
- A 45-year-old male patient experienced recurrent MPGN type I in two successive renal grafts.
- The recurrence presented with increased proteinuria and creatinine, confirmed by biopsy.
- Complement levels showed a further decrease in C3 and C4 during recurrence.
Findings:
- Treatment with plasmapheresis (PP) and rituximab was initiated for the recurrent MPGN.
- Initial treatment showed reduced acute lesions on biopsy.
- A subsequent cycle of PP and rituximab stabilized renal function one year later.
Implications:
- This case highlights the potential efficacy of combined plasmapheresis and rituximab in managing recurrent MPGN post-transplantation.
- The findings suggest a viable therapeutic strategy for a challenging clinical scenario in kidney transplantation.
- Further research into optimal treatment protocols for recurrent MPGN is warranted.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Acute Kidney Injury III: Clinical Manifestations
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Acute Kidney Injury II: Pathophysiology
Kidney Transplant I: Introduction
